Amphastar Pharmaceuticals financials
$26.68−2.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $183.9M | $171.2M | $183.1M | $191.8M | $174.4M | $170.5M | $186.5M | $191.2M | $182.4M | $171.8M | $178.1M | $180.6M |
| Gross profit | $93.5M | $70.3M | $85.7M | $98.6M | $86.5M | $85.3M | $86.6M | $101.9M | $95.2M | $90.1M | $96.1M | $108.4M |
| Gross margin | 50.8% | 41.1% | 46.8% | 51.4% | 49.6% | 50.0% | 46.5% | 53.3% | 52.2% | 52.4% | 54.0% | 60.0% |
| Operating income | $39.7M | $13.6M | $35.6M | $25.3M | $42.2M | $37.3M | $45.1M | $57.0M | $55.2M | $48.0M | $54.0M | $72.7M |
| Net income | $30.3M | $6.4M | $24.4M | $17.4M | $31.0M | $25.3M | $38.0M | $40.4M | $37.9M | $43.2M | $36.2M | $49.2M |
| Net margin | 16.5% | 3.8% | 13.3% | 9.0% | 17.8% | 14.8% | 20.4% | 21.1% | 20.8% | 25.1% | 20.3% | 27.3% |
| Diluted EPS | $0.67 | $0.14 | $0.52 | $0.37 | $0.64 | $0.51 | $0.83 | $0.78 | $0.73 | $0.81 | $0.68 | $0.91 |
| EBITDA | $54.0M | $28.0M | $49.9M | $39.4M | $56.8M | $50.9M | $58.6M | $70.4M | $68.4M | $61.0M | $54.0M | $85.3M |
| Operating cash flow | $51.3M | $47.8M | $32.9M | $52.6M | $35.6M | $35.1M | $29.0M | $60.0M | $69.1M | $55.3M | $23.9M | $64.3M |
| Free cash flow | $42.7M | $38.3M | $24.6M | $47.2M | $25.0M | $24.4M | $16.6M | $46.2M | $63.1M | $46.5M | $14.4M | $54.1M |
| Diluted shares | 44.2M | 46.5M | 47.2M | 47.7M | 48.1M | 49.9M | 45.6M | 51.9M | 52.0M | 58.8M | 53.0M | 53.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $223.6M | $170.9M | $170.2M | $216.3M | $187.7M | $182.8M |
| Short-term investments | $66.5M | $121.0M | $112.6M | $59.9M | $44.1M | $54.1M |
| Total debt | $612.1M | $611.5M | $610.4M | $609.5M | $608.7M | $604.1M |
| Total assets | $1.74B | $1.65B | $1.63B | $1.67B | $1.62B | $1.63B |
| Total liabilities | $975.6M | $874.8M | $840.5M | $889.5M | $857.9M | $875.0M |
| Shareholders' equity | $768.2M | $773.4M | $788.8M | $776.7M | $757.5M | $751.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology